Amylyx Pharmaceuticals, Inc./$AMLX

1D1W1MYTD1Y5YMAX

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Ticker
$AMLX
Sector
Health
Primary listing
NASDAQ
Employees
136
Headquarters
Cambridge, United States
Website
amylyx.com

AMLX Metrics

BasicAdvanced
$4.2B
-
-$1.43
-0.12
-

Bulls say / Bears say

Avexitide produced a strong Phase 3 LUCIDITY result, reducing composite Level 2 and Level 3 hypoglycemic events by 55% versus placebo with a p-value of 0.000003, and met all reported secondary endpoints. (Amylyx)
Amylyx plans to submit an avexitide NDA by the end of 2026, while the drug has FDA Breakthrough Therapy and Orphan Drug designations, potentially accelerating review and supporting a targeted 2027 launch if approved. (Amylyx)
The company reported $250.8 million of cash, cash equivalents, and marketable securities as of June 30, 2026, and expects those resources to fund operations into 2028, reducing immediate financing pressure during the regulatory process. (SEC)
Amylyx remains unprofitable and had a $84.7 million net loss and $68.3 million of operating cash burn in the six months ended June 30, 2026, leaving valuation dependent on future product approval and commercialization. (SEC)
Although LUCIDITY was positive, it enrolled only 78 participants and avexitide remains investigational; the company still faces FDA review, labeling, manufacturing, and launch-execution risks before any revenue can be generated. (Amylyx)
The broader pipeline provides limited near-term diversification: AMX0035 in Wolfram syndrome is based on a 12-participant open-label Phase 2 study, while AMX0114 remains in Phase 1, increasing dependence on avexitide's regulatory and commercial success. (Amylyx)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.

AMLX News

AllArticlesVideos

20 stocks likely to lose money even if the bull market continues

Market Watch3 weeks ago

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Business Wire4 weeks ago

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Business Wire4 weeks ago

Funds containing AMLX

AllGBPUSDEUR
Funds
Fund name
Fund size
$AMLX weighting
Xtrackers S&P 500 Swap£XSPX
£3.1B0.35%
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.25%
iShares Nasdaq US Biotechnology£BTEK
£865M0.25%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.11%
iShares MSCI World Small Cap$WSML
$9B0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.